Cure My Disease

Don't miss your cure!

 Log in / Sign up

New registry to monitor Long-Term effects of C5 inhibitors in myasthenia gravis

NCT ID NCT04202341

Knowledge-focused Sponsor: Alexion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is a long-term, global registry that follows 500 people with generalized myasthenia gravis who are taking or have taken C5 inhibitor drugs like Soliris or Ultomiris. The goal is to collect real-world data on safety and how well the treatment helps with daily activities over time. Participants must have a confirmed diagnosis and some historical medical records available. No new treatments are given; this is purely observational.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2019

Expected to finish

Oct 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants with a diagnosis of gMG who are treated with Alexion C5IT at the time of enrollment, or have ever been treated with Alexion C5IT prior to enrollment, and meet the inclusion criteria and exclusion criteria are eligible for registry participation.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participants with a diagnosis of gMG who are treated with Alexion C5IT at the time of enrollment, including patients previously treated with Soliris or Ultomiris and withdrawn from treatment. 2. Capable of giving signed informed consent, which includes compliance with the protocol requirements and restrictions. 3. Participants must have myasthenia gravis historical data, such as MG-ADL and MGFA class, available to be enrolled in the Registry. Exclusion Criteria: 1\. Participants currently enrolled in an Alexion-sponsored interventional clinical study for treatment of gMG cannot be enrolled in the Alexion gMG Registry while enrolled/participating in the clinical study for gMG therapy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Generalized myasthenia gravis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Generalized myasthenia gravis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    51 sites in 7 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Clincal Trial Site

    RECRUITING

    Gainesville, Florida, 32608, United States

  • Clinical Trial Site

    RECRUITING

    Birmingham, Alabama, 35294, United States

  • Clinical Trial Site

    RECRUITING

    Scottsdale, Arizona, 85251, United States

  • Clinical Trial Site

    RECRUITING

    Fresno, California, 93710, United States

  • Clinical Trial Site

    RECRUITING

    Orange, California, 92868, United States

  • Clinical Trial Site

    RECRUITING

    Rancho Mirage, California, 92270, United States

  • Clinical Trial Site

    RECRUITING

    Sylmar, California, 91342, United States

  • Clinical Trial Site

    RECRUITING

    Colorado Springs, Colorado, 80907, United States

  • Clinical Trial Site

    RECRUITING

    Fort Collins, Colorado, 80528, United States

  • Clinical Trial Site

    RECRUITING

    New Haven, Connecticut, 06520, United States

  • Clinical Trial Site

    RECRUITING

    Washington D.C., District of Columbia, 10010, United States

  • Clinical Trial Site

    RECRUITING

    Clearwater, Florida, 33761, United States

  • Clinical Trial Site

    RECRUITING

    Jacksonville, Florida, 32209, United States

  • Clinical Trial Site

    RECRUITING

    Tampa, Florida, 33612, United States

  • Clinical Trial Site

    RECRUITING

    Augusta, Georgia, 30912, United States

  • Clinical Trial Site

    RECRUITING

    Iowa City, Iowa, 52242, United States

  • Clinical Trial Site

    RECRUITING

    Lexington, Kentucky, 40503, United States

  • Clinical Trial Site

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • Clinical Trial Site

    RECRUITING

    Lansing, Michigan, 48824, United States

  • Clinical Trial Site

    RECRUITING

    Columbia, Missouri, 65212, United States

  • Clinical Trial Site

    RECRUITING

    New Hyde Park, New York, 11042, United States

  • Clinical Trial Site

    RECRUITING

    Chapel Hill, North Carolina, 27599, United States

  • Clinical Trial Site

    RECRUITING

    Charlotte, North Carolina, 28207, United States

  • Clinical Trial Site

    RECRUITING

    Durham, North Carolina, 27705, United States

  • Clinical Trial Site

    RECRUITING

    Dayton, Ohio, 45459, United States

  • Clinical Trial Site

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • Clinical Trial Site

    RECRUITING

    Chattanooga, Tennessee, 37403, United States

  • Clinical Trial Site

    RECRUITING

    Knoxville, Tennessee, 37920, United States

  • Clinical Trial Site

    RECRUITING

    Dallas, Texas, 75206, United States

  • Clinical Trial Site

    RECRUITING

    Houston, Texas, 77030, United States

  • Clinical Trial Site

    RECRUITING

    Burlington, Vermont, 05401, United States

  • Clinical Trial Site

    RECRUITING

    Milwaukee, Wisconsin, 53215, United States

  • Clinical Trial Site

    RECRUITING

    Vienna, 1090, Austria

  • Clinical Trial Site

    RECRUITING

    Brampton, Ontario, L6R 3J7, Canada

  • Clinical Trial Site

    RECRUITING

    London, Ontario, N6A 5A5, Canada

  • Clinical Trial Site

    RECRUITING

    Montreal, Quebec, H2X 3E4, Canada

  • Clinical Trial Site

    RECRUITING

    Chengdu, Sichuan, 610041, China

  • Clinical Trial Site

    RECRUITING

    Beijing, 100730, China

  • Clinical Trial Site

    RECRUITING

    Changchun, 130021, China

  • Clinical Trial Site

    RECRUITING

    Chengdu, 610072, China

  • Clinical Trial Site

    RECRUITING

    Guangzhou, 510080, China

  • Clinical Trial Site

    RECRUITING

    Jinan, 250021, China

  • Clinical Trial Site

    RECRUITING

    Nanchang, 330006, China

  • Clinical Trial Site

    RECRUITING

    Qingdao, 266003, China

  • Clinical Trial Site

    RECRUITING

    Shijiazhuang, 050000, China

  • Clinical Trial Site

    RECRUITING

    Hanover, Hannover, 30625, Germany

  • Clinical Trial Site

    RECRUITING

    Milan, 20133, Italy

  • Clinical Trial Site

    RECRUITING

    Naples, 80138, Italy

  • Clinical Trial Site

    RECRUITING

    Abhā, 62523, Saudi Arabia

  • Clinical Trial Site

    RECRUITING

    Jeddah, 22384, Saudi Arabia

  • Clinical Trial Site

    RECRUITING

    Riyadh, 14611, Saudi Arabia

More trials for these conditions

Other studies related to the condition(s) this trial covers.